...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

** BETonMACE Phase 3 Cardio Outcomes Trial for Apabetalone Has Reached its Targeted 250 MACE Events ** Top-Line Data Expected Mid-Year 2019 https://clinicaltrials.gov/ct2/show/NCT02586155

Message: Lilly to Discontinue Development of Evacetrapib

Looks like he is really sticking the knife in. "Lilly's Evacetrapib best ever in biological effect" "Very unlikely other CETP inhibitors will work". I bet Merck is pleased with those comments!

New Message
Please login to post a reply